Screener Summaries Updates Institutions Sign In More Updates › Other Events › SNY Other Events · Jul 7, 2026
Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease SNY Sanofi
Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease. Sanofi is a global healthcare company specializing in pharmaceutical research and development.
All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
